Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MDGL |
---|---|---|
09:32 ET | 1355 | 260 |
09:34 ET | 225 | 262.25 |
09:39 ET | 200 | 259 |
09:41 ET | 1689 | 260.46 |
09:43 ET | 16708 | 260 |
09:45 ET | 100 | 260.07 |
09:48 ET | 500 | 260.515 |
09:50 ET | 597 | 257.63 |
09:52 ET | 200 | 256.95 |
09:54 ET | 100 | 259.5 |
09:56 ET | 150 | 259.8599 |
09:57 ET | 100 | 257.16 |
09:59 ET | 900 | 257.805 |
10:01 ET | 300 | 259.61 |
10:03 ET | 1487 | 259.6 |
10:06 ET | 360 | 258.54 |
10:08 ET | 315 | 258.48 |
10:10 ET | 1791 | 257.575 |
10:12 ET | 100 | 258.32 |
10:14 ET | 754 | 257 |
10:15 ET | 800 | 255 |
10:17 ET | 600 | 254.895 |
10:19 ET | 500 | 255.905 |
10:26 ET | 620 | 257.08 |
10:28 ET | 600 | 257.6 |
10:30 ET | 100 | 257.71 |
10:32 ET | 100 | 257.72 |
10:35 ET | 100 | 257.52 |
10:37 ET | 2193 | 256.71 |
10:39 ET | 600 | 257.025 |
10:42 ET | 950 | 256.99 |
10:44 ET | 100 | 257.3 |
10:46 ET | 100 | 257.35 |
10:48 ET | 300 | 256.93 |
10:53 ET | 100 | 256.44 |
11:00 ET | 500 | 256.635 |
11:04 ET | 100 | 256.475 |
11:06 ET | 100 | 257.05 |
11:08 ET | 1100 | 258.31 |
11:09 ET | 250 | 258.1 |
11:11 ET | 692 | 257.945 |
11:13 ET | 900 | 256.91 |
11:15 ET | 535 | 257.274 |
11:18 ET | 100 | 256.5 |
11:20 ET | 100 | 257.15 |
11:24 ET | 300 | 257.055 |
11:26 ET | 300 | 257.505 |
11:27 ET | 201 | 257.98 |
11:38 ET | 100 | 257.62 |
11:44 ET | 800 | 256.93 |
11:45 ET | 941 | 256.1 |
11:49 ET | 518 | 255.56 |
12:02 ET | 200 | 255.035 |
12:03 ET | 761 | 254.035 |
12:05 ET | 875 | 254.49 |
12:07 ET | 304 | 254.39 |
12:14 ET | 2161 | 253.53 |
12:16 ET | 1153 | 252.67 |
12:18 ET | 100 | 252.27 |
12:21 ET | 100 | 253.45 |
12:23 ET | 700 | 252.8 |
12:27 ET | 2100 | 252.665 |
12:30 ET | 300 | 253 |
12:32 ET | 469 | 253.137 |
12:34 ET | 250 | 253.55 |
12:38 ET | 500 | 253.89 |
12:43 ET | 200 | 255.38 |
12:45 ET | 100 | 254.84 |
12:48 ET | 533 | 254.79 |
12:50 ET | 100 | 254.905 |
12:52 ET | 100 | 254.78 |
12:56 ET | 1875 | 255.2075 |
12:57 ET | 505 | 255.55 |
12:59 ET | 100 | 254.72 |
01:01 ET | 1796 | 255.33 |
01:03 ET | 300 | 254.79 |
01:10 ET | 400 | 255.48 |
01:12 ET | 100 | 255.85 |
01:15 ET | 100 | 255.525 |
01:19 ET | 506 | 256 |
01:21 ET | 790 | 256.679 |
01:30 ET | 200 | 256.51 |
01:35 ET | 100 | 256.98 |
01:39 ET | 350 | 257.99 |
01:42 ET | 3809 | 257.19 |
01:44 ET | 100 | 256.64 |
01:46 ET | 2871 | 256.585 |
01:48 ET | 200 | 256.585 |
01:50 ET | 2400 | 257 |
01:51 ET | 1500 | 257 |
01:53 ET | 970 | 257.305 |
01:55 ET | 201 | 257.315 |
02:00 ET | 100 | 258.1 |
02:02 ET | 2013 | 257.495 |
02:04 ET | 414 | 258.06 |
02:06 ET | 200 | 257.945 |
02:08 ET | 200 | 257.975 |
02:09 ET | 100 | 258.185 |
02:11 ET | 200 | 258.69 |
02:13 ET | 100 | 258.345 |
02:15 ET | 230 | 258.365 |
02:18 ET | 100 | 258.375 |
02:24 ET | 200 | 259 |
02:27 ET | 400 | 258.53 |
02:29 ET | 300 | 258.46 |
02:38 ET | 210 | 258.34 |
02:45 ET | 100 | 257.99 |
02:51 ET | 510 | 257.88 |
02:54 ET | 400 | 258.21 |
03:00 ET | 200 | 258.14 |
03:02 ET | 100 | 257.545 |
03:05 ET | 8848 | 256.175 |
03:07 ET | 125 | 256.48 |
03:14 ET | 100 | 256.98 |
03:18 ET | 300 | 256.61 |
03:20 ET | 200 | 256.8 |
03:25 ET | 100 | 256.03 |
03:27 ET | 100 | 256.16 |
03:30 ET | 100 | 256.135 |
03:34 ET | 100 | 256.69 |
03:39 ET | 576 | 256.7 |
03:41 ET | 100 | 257.23 |
03:48 ET | 202 | 256.07 |
03:50 ET | 300 | 256.43 |
03:52 ET | 300 | 256.725 |
03:54 ET | 800 | 257.245 |
03:56 ET | 800 | 256.03 |
03:57 ET | 5062 | 255.24 |
03:59 ET | 20975 | 256.17 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Madrigal Pharmaceuticals Inc | 5.6B | -10.0x | --- |
Nuvalent Inc | 5.4B | -29.7x | --- |
Avidity Biosciences Inc | 5.2B | -15.2x | --- |
Krystal Biotech Inc | 5.8B | 55.2x | --- |
Immunovant Inc | 4.8B | -16.9x | --- |
BridgeBio Pharma Inc | 4.8B | -9.7x | --- |
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.6B |
---|---|
Revenue (TTM) | $14.6M |
Shares Outstanding | 21.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.43 |
EPS | $-25.50 |
Book Value | $20.39 |
P/E Ratio | -10.0x |
Price/Sales (TTM) | 380.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,622.65% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.